Skip to Main Content

Paper Details

A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
ESMO Open
2
2021
Author NameAffiliation
Celestia S HiganoUniversity of Washington
David I QuinnUniversity of Southern California Norris Comprehensive Cancer Center
Oliver SartorTulane Cancer Center, Tulane University School of Medicine
  • 1 - 3

Datasets

Release 1.2